Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global animal and human serum market size was valued at USD 2.4 billion in 2024. The market is projected to grow from USD 2.6 billion in 2025 to USD 4.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% during the forecast period.
Animal and human sera are vital biological materials that serve as a source of nutrients, hormones, growth factors, and attachment factors for cells cultured in vitro. Fetal Bovine Serum (FBS) is the most widely used growth supplement, prized for its high content of growth-promoting components. Conversely, Human Serum Albumin (HSA) is a critical blood-derived product used as a plasma volume expander and a stabilizer in pharmaceutical formulations. These products are indispensable across biotechnology, pharmaceutical development, and advanced clinical diagnostics, as well as in the rapidly expanding field of veterinary medicine. The global animal health industry, a key driver for animal serum, was valued at USD 38.3 billion in 2021, underscoring the significant demand.
Market growth is fueled by the expanding biopharmaceutical sector and increasing investments in life sciences research and development. However, the industry faces challenges such as the high cost of FBS and ethical concerns regarding its sourcing, which is driving research into serum-free and animal-component-free alternatives. Furthermore, the growth in pet ownership and an aging pet population is creating substantial demand in veterinary medicine. For instance, in the UK, annual spending on veterinary services rose 54% from £2.6 billion in 2015 to £4 billion in 2021. Key market players like Thermo Fisher Scientific, Merck KGaA, and Grifols are actively engaged in expanding their product portfolios and ensuring a consistent supply of high-quality, traceable serum products to meet stringent regulatory standards.
Rising Demand for Biopharmaceuticals and Cell-Based Therapies
The global push for advanced biologics, including vaccines, monoclonal antibodies, and regenerative medicines, is a primary driver. Serum, particularly Fetal Bovine Serum (FBS), remains an essential growth medium component for cell culture in R&D and biomanufacturing. This demand is amplified by increasing investments in pharmaceutical and biotechnology research worldwide, with the cell culture market projected to grow significantly over the next decade.
Expansion of the Life Sciences and Diagnostics Industry
Human serum is critical for diagnostic applications, including immunoassays, clinical chemistry tests, and as a control material. The growing prevalence of chronic and infectious diseases necessitates extensive diagnostic testing, fueling demand. Similarly, veterinary diagnostics and vaccine production rely heavily on animal sera, supporting market growth.
➤ The increasing adoption of 3D cell culture and organoid technologies is further driving the need for high-quality, standardized serum products to ensure consistent and reliable research outcomes.
Technological advancements in serum processing and the development of specialty serum products, such as charcoal-stripped or exosome-depleted serum, are meeting more specific research needs and creating new revenue streams.
MARKET CHALLENGES
Ethical, Supply, and Regulatory Hurdles
The procurement of animal serum, especially FBS, faces significant ethical scrutiny and regulatory complexity. Concerns over animal welfare have led to stricter regulations and a growing push for alternatives. Supply chain volatility, influenced by factors like disease outbreaks in cattle herds and export restrictions, creates price instability and potential shortages.
Other Challenges
High Cost and Batch-to-Batch Variability
Serum is one of the most expensive components of cell culture media. Furthermore, inherent variability between serum batches can compromise experimental reproducibility, posing a major challenge for researchers requiring consistent results in drug discovery and manufacturing.
Shift Towards Serum-Free Alternatives
The scientific community is actively developing and adopting serum-free media (SFM) and chemically defined media to overcome the limitations of serum. While this represents a long-term opportunity, it simultaneously challenges the traditional serum market by cannibalizing demand, particularly in regulated bioproduction.
Stringent Regulatory Oversight and Safety Concerns
Serum products are subject to rigorous quality control and regulatory standards from bodies like the FDA and EMA to prevent contamination with adventitious agents (e.g., viruses, prions). This increases production costs and time-to-market. The risk of transmitting zoonotic diseases via animal serum acts as a significant restraint, especially for therapeutics intended for human use.
Price Sensitivity and Raw Material Sourcing Limitations
The market is constrained by the high cost of high-quality serum, which can be prohibitive for academic institutions and smaller biotech firms. Sourcing restrictions, such as bans on the import of bovine serum from countries with BSE risk, limit the geographical supply base and contribute to market fragmentation and price pressures.
Growth in Emerging Markets and Personalized Medicine
Expanding biotechnology and pharmaceutical sectors in Asia-Pacific regions, particularly in China and India, present substantial growth opportunities. These countries are increasing their domestic production capabilities and R&D investments, driving demand for both animal and human serum products.
Innovation in Serum Products and Alternatives
There is a significant opportunity for companies to develop value-added serum products with enhanced characteristics, such as defined growth factors or reduced immunoglobulin levels, tailored for specific applications. Additionally, companies that can effectively bridge the market by offering both traditional sera and advanced serum-free solutions are well-positioned to capture a broader customer base.
Application in Advanced Therapeutic Medicinal Products (ATMPs)
The burgeoning field of cell and gene therapies (CGTs) requires high-quality raw materials for cell expansion. While moving towards serum-free, the current reliance on serum for many processes creates a robust, short-to-mid-term market. Providers of clinical-grade, traceable sera that meet Good Manufacturing Practice (GMP) standards are essential partners in this high-growth sector.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Fetal Bovine Serum (FBS) commands a leading position due to its extensive application as a critical cell culture supplement in biopharmaceutical manufacturing and life sciences research. Its superior growth-promoting properties and consistency make it an indispensable raw material. The Human Serum Albumin segment is also vital, primarily driven by its therapeutic uses in clinical settings for volume expansion and drug formulation, supported by established pharmaceutical supply chains. |
| By Application |
|
Pharmaceutical & Biotechnology Companies represent the most significant application segment, as they are the primary consumers of sera for vaccine development, monoclonal antibody production, and advanced therapeutic research. The robust pipeline of biologics and cell-based therapies underpins sustained demand. Diagnostic Laboratories also constitute a major segment, utilizing sera for assay development and quality control, while Hospitals and Clinics primarily use therapeutic serum products like albumin. |
| By End User |
|
Human Healthcare is the dominant end-user segment, driven by the critical need for serum-based therapeutics and diagnostics in treating various human diseases. The segment benefits from continuous medical advancements and high healthcare expenditure. The Veterinary Care segment is experiencing notable growth, fueled by the increasing trend of pet humanization, rising spending on advanced pet medical care, and the growing population of aging pets requiring more sophisticated treatments. |
| By Quality Grade |
|
GMP Grade serum is the leading segment due to its stringent quality control and documentation, which are mandatory for use in therapeutic product manufacturing and clinical applications. The demand for this high-assurance grade is strongly correlated with the expansion of the biologics market and regulatory requirements. Research Grade serum, while a large volume segment, is primarily used in basic research where regulatory compliance is less critical, highlighting a distinct market dynamic based on application rigor. |
| By Supply Chain Role |
|
End-Use Customers form the foundational driver of the market, with their demand dictating production and distribution activities. The critical need for reliable serum from pharmaceutical companies and research institutes creates a stable, high-value market. Manufacturers hold a pivotal position, as their ability to ensure a consistent, ethically sourced, and high-quality supply is a key competitive differentiator. Distributors and Suppliers are essential for global market reach and ensuring product availability, especially for specialized research-grade products. |
A Consolidated Market with Global Leaders and Specialized Niche Players
The global Animal and Human Serum market is characterized by a mix of large, diversified life science corporations and specialized manufacturers. Leading players such as Thermo Fisher Scientific, Merck (including its MilliporeSigma brand), and Cytiva (a Danaher company) dominate through their extensive product portfolios, global distribution networks, and strong R&D capabilities, particularly in the high-volume Fetal Bovine Serum (FBS) segment. These established giants benefit from economies of scale and long-standing relationships with major pharmaceutical companies and academic research institutions, giving them a significant market share. The competitive environment is further shaped by companies like Grifols, CSL, and Octapharma, which are major forces in the human plasma-derived products segment, including Human Serum Albumin.
Beyond the global leaders, a substantial number of specialized and regional players compete effectively by focusing on niche applications, specific serum types, or geographic markets. Companies such as Biowest, Moregate BioTech, and Tissue Culture Biologicals have carved out strong positions by offering high-quality, characterized sera and tailored solutions for specialized cell culture applications. In regions like Asia-Pacific, companies including Hualan Bio, China National Biotec Group (CNBG), and Shanghai RAAS are significant players, capitalizing on growing domestic demand. Other notable participants like Gemini Bio, Biological Industries (part of Sartorius), and Corning provide essential products and contribute to the market's competitive diversity, often competing on quality, traceability, and customer service rather than price alone.
List of Key Animal and Human Serum Companies ProfiledGrifols, S.A.
CSL Behring
Octapharma AG
Biotest AG
Moregate BioTech
Gemini Bio
Biological Industries (Sartorius)
Corning Incorporated
Hualan Biological Engineering Inc.
China National Biotec Group (CNBG)
Shanghai RAAS Blood Products Co., Ltd.
Tissue Culture Biologicals
Animal Technologies
The global animal and human serum market is experiencing significant growth, driven in large part by the expansion of the veterinary and pet care industry. According to Vetnosis, the value of the global animal health industry increased by 12% to $38.3 billion in 2021, underscoring a substantial demand for related biological products like serum. This is amplified by the trend of pet aging. Data from JD's White Paper on China's Pet Healthy Consumption indicates that over 13 million pets entered middle and old age in 2023, a demographic change that directly increases the need for medical care and diagnostic services, thereby fueling demand for animal serum in therapeutics and diagnostics. The scale of China's pet medical market was approximately ¥67.5 billion in 2022, accounting for 22.5% of the entire pet industry.
Other TrendsMarket Expansion and Segment Dynamics
Market growth is further segmented by product type and application. Fetal Bovine Serum (FBS) and Human Serum Albumin (HSA) are key product segments. The application of these serums spans hospitals, clinics, and diagnostic laboratories, with the latter seeing increased use as preventative and diagnostic care for pets becomes more common. Nearly 40% of pet hospitals reported a year-on-year increase in annual turnover, indicating a healthy and expanding operational environment that supports serum product sales. Geographically, Asia, particularly China, represents a high-growth region due to its rapidly developing pet healthcare infrastructure.
Regulatory and Supply Chain ConsiderationsThe market's growth is not without challenges. Industry participants, including major players like Thermo Fisher, Merck, and Grifols, must navigate complex regulatory landscapes and ensure a consistent, high-quality supply of raw materials. The concentration of a significant portion of the market among the top five companies highlights the competitive nature of the industry, where quality control, adherence to stringent safety standards, and strategic mergers and acquisitions are critical for maintaining market position. The global market is projected to continue its growth trajectory towards 2032, with manufacturers focusing on innovation and strategic partnerships to meet rising global demand.
Regional Analysis: Animal and Human Serum MarketEurope
Europe represents a mature and highly sophisticated market for animal and human serum, characterized by a strong regulatory framework similar to North America's. The market is driven by a well-funded academic research sector, a prominent pharmaceutical industry, and growing cell and gene therapy activities. Countries like Germany, the UK, and France are major hubs. A significant focus within the region is on the ethical sourcing of animal sera, with increasing demand for alternatives and serum-free media, influenced by strong animal welfare regulations. The European Medicines Agency (EMA) provides stringent oversight, ensuring high product quality and safety. The market also benefits from collaborative cross-border research initiatives funded by the EU, which sustains demand for high-quality biological reagents.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for animal and human serum, fueled by rapidly expanding biotechnology and pharmaceutical sectors, increasing government investments in healthcare research, and the outsourcing of clinical trials and manufacturing. Countries such as China, India, Japan, and South Korea are key growth engines. China, in particular, has become a major producer and consumer of fetal bovine serum. The region offers cost-competitive manufacturing and a large patient population for clinical research. However, market dynamics include variability in regulatory standards and quality control compared to Western markets, which presents both a challenge and an opportunity for standardization and growth as the region continues to develop its regulatory frameworks.
South America
South America's market is characterized by its role as a significant source region for fetal bovine serum, particularly from countries like Brazil, Argentina, and Uruguay, which have large cattle industries. While local consumption is growing steadily with developing biotech sectors, especially in Brazil, the region is predominantly an exporter of raw serum materials to North America, Europe, and Asia. The market faces challenges related to economic volatility and infrastructure limitations, which can impact the consistency of supply and distribution. Nevertheless, the availability of raw materials presents a strategic advantage, and there is potential for growth in local value-added processing and manufacturing of serum-based products in the future.
Middle East & Africa
This region currently represents a smaller but emerging market for animal and human serum. Growth is primarily driven by increasing government initiatives to develop local pharmaceutical and biotechnology capabilities, particularly in Gulf Cooperation Council (GCC) countries like Saudi Arabia and the UAE. South Africa has a more established research base. The market is largely import-dependent for high-quality, characterized serum products. Challenges include limited local manufacturing capacity, logistical hurdles, and varying regulatory environments. However, rising investments in healthcare infrastructure and a growing focus on life sciences research indicate potential for gradual market expansion over the coming years.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global animal and human serum market was valued at USD 2.4 billion in 2024 and is projected to reach USD 4.1 billion by 2032.
Which key companies operate in Global Animal and Human Serum Market?
-> Key players include Thermo Fisher Scientific, Merck KGaA, Grifols, CSL, and Baxter, among others.
-> Key growth drivers include expanding biopharmaceutical sector, increasing life sciences R&D investments, and growth in pet healthcare spending.
-> North America currently leads the market, while Asia-Pacific shows the fastest growth rate.
-> Emerging trends include development of serum-free alternatives, traceability solutions, and increasing demand from veterinary medicine sector.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates